Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Gilead gets ball rolling on JAKs game in Japan
Endpoints
Mon, 12/30/19 - 10:39 am
Tags:
Gilead Sciences, Japan, filgotinib, Eisai, rheumatoid arthritis
As promised, Gilead and Galapagos file filgotinib to FDA and get a speedy review
Fierce Biotech
Fri, 12/20/19 - 12:29 pm
Tags:
Gilead Sciences, FDA, filgotinib, Galapagos, rheumatoid arthritis
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
Thu, 12/19/19 - 01:11 pm
Tags:
gene therapy, reimbursement, drug manufacturing, Bristol-Myers Squibb, Pfizer, Biomarin, Sarepta Therapeutics, Gilead Sciences, CAR-T
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
Tags:
NASH, Genfit, elafibranor, Pfizer, Boehringer Ingelheim, Gilead Sciences, Poxel, Takeda, Intercept Pharma
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Reuters
Fri, 12/13/19 - 09:09 pm
Tags:
Bristol-Myers Squibb, Gilead Sciences, Kite Pharma, patents, Juno Therapeutics
Attorney misconduct allegations crop up in Johnson & Johnson, Gilead cases
Fierce Pharma
Fri, 12/13/19 - 12:13 pm
Tags:
attorneys, JNJ, Gilead Sciences
Gilead's Kite files for FDA approval of second CAR-T therapy
Fierce Biotech
Thu, 12/12/19 - 11:27 am
Tags:
Gilead Sciences, KTE-X19, mantle cell lymphoma, CAR-T, Kite Pharma
For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans
Biopharma Dive
Tue, 12/10/19 - 11:51 pm
Tags:
M&A, Gilead Sciences, Kite
ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
Fierce Pharma
Sun, 12/8/19 - 10:13 pm
Tags:
Gilead Sciences, Yescarta, ASH2019, CAR-T, refractory large B-cell lymphoma
Activists seek to block a Gilead patent extension on a lucrative HIV drug
Stat
Fri, 12/6/19 - 09:52 am
Tags:
Gilead Sciences, patents, HIV, activists, TAF
Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst
Fierce Pharma
Tue, 12/3/19 - 10:31 pm
Tags:
Gilead Sciences, HIV, PrEP, Truvada, Descovy
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Mon, 11/25/19 - 09:49 pm
Tags:
Amarin, M&A, Novartis, Medicines Company, Gilead Sciences
Does Amarin Have a Dark Horse Suitor?
Motley Fool
Sun, 11/24/19 - 11:32 pm
Tags:
Amarin, Vascepa, M&A, Gilead Sciences
Gilead CEO Daniel O'Day says company is in an 'acquisitive mode'
Stat
Wed, 11/20/19 - 10:43 pm
Tags:
Gilead Sciences, Daniel O'Day, Pharma CEOs, M&A
Will Its HIV Lineup Save Gilead Sciences?
Motley Fool
Mon, 11/11/19 - 07:50 pm
Tags:
Gilead Sciences, HIV, Descovy, Biktarvy
AASLD: Gilead wants to move the needle for fatty liver therapies
Fierce Biotech
Mon, 11/11/19 - 10:46 am
Tags:
Gilead Sciences, NASH, selonsertib, clinical trials, AASLD
HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills
Stat
Thu, 11/7/19 - 10:29 am
Tags:
Gilead Sciences, HIV, HHS, Truvada, Descovy
Gilead’s Matthew Sause to Join Roche Diagnostics as North America CEO
Xconomy
Wed, 10/30/19 - 10:56 pm
Tags:
Roche Diagnostics, Matthew Sause, Gilead Sciences
Merck loses bid to revive $2.54 billion patent verdict against Gilead
Yahoo/Reuters
Wed, 10/30/19 - 10:11 am
Tags:
Merck, Gilead Sciences, patents, hepatitis C
Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers
BioSpace
Tue, 10/29/19 - 10:23 am
Tags:
San Francisco, Bay Area, Genentech, Gilead Sciences, Roche, Amgen

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.